The growing incidence and prevalence of diabetes has made a significant impact on the development of diabetic kidney disease (DKD) (1). DKD is among the most frequent complications of diabetes; indeed, diabetes accounts for ~50% of all cases of end-stage renal disease (ESRD) in developed countries (2). Patients often have comorbid diabetes and chronic kidney disease (CKD). Although intensive glycemic management has been shown to delay the onset and progression of increased urinary albumin excretion and reduced estimated glomerular filtration rate (eGFR) in diabetes patients (3), conservative dose selection and adjustment of antidiabetic medications is necessary to balance glycemic control with safety.

Role of A1C in DKD

A1C has limitations related to its precision and interpretation in the CKD population (4), with erythrocyte turnover being a major cause of A1C imprecision in this population. Red blood cell survival times become shorter as eGFR falls, resulting in a reduction in measured A1C. Treatment with erythrocyte-stimulating agents lowers A1C further, perhaps because of changes in hemoglobin concentrations (5,6).

Observational data support the notion that higher A1C levels in nondialysis diabetes patients with CKD stages 3–5 (eGFR levels <60 mL/min/1.73 m²) are associated with worse outcomes, including progression of kidney disease (7). However, these patients are at higher risk for hypoglycemic events (8). Factors that may contribute to this increased risk can include slowed elimination of hypoglycemic agents, alcohol intake, chronic malnutrition, acute caloric deprivation, and decreased renal gluconeogenesis as kidney function declines (8–10). In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, when compared with patients with normal renal function, those with baseline serum creatinine of 1.3–1.5 mg/dL had a 66% increased risk of severe hypoglycemia (11). A U-shaped relationship between A1C and mortality has been demonstrated, suggesting that hypoglycemia may be one reason for higher mortality in those with A1C levels <6.5% (7,12,13).

Although A1C levels between ~7 and 8% appear to be associated with the highest survival rates in retrospective studies of DKD patients, the previously highlighted limitations of A1C in the setting of DKD makes A1C goal-setting difficult (8). Despite the inherent limitations of A1C measurement, however, A1C remains a key monitoring parameter in the glycemic management of people with DKD (12). Importantly, an A1C that is low or trending lower because of a decrease in kidney function may be interpreted as improved glycemic control, when it actually may be an ominous sign of kidney disease progression. Ultimately, A1C results should be interpreted carefully.

Management of Hyperglycemia in Diabetic Kidney Disease

Joshua J. Neumiller and Irl B. Hirsch

1Washington State University, College of Pharmacy, Spokane, WA
2University of Washington, Division of Metabolism, Endocrinology, and Nutrition, Seattle, WA

Corresponding author: Joshua J. Neumiller, jneumiller@wsu.edu

DOI: 10.2337/diaspect.28.3.214

©2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
Use of Drug Therapies for Glycemic Control

As previously noted, the risk of hypoglycemia is increased in people with DKD whose eGFR is < 60 mL/min/1.73 m², in part because of decreased clearance of antidiabetic agents and decreased gluconeogenesis by the kidney (9,10). Accordingly, dose adjustments are required for many antidiabetic agents when used in people with DKD. Table 1 provides a summary of dosing recommendations for noninsulin antidiabetic agents currently available in the United States (8,10,14).

**TABLE 1. Dosing Recommendations for Noninsulin Antihyperglycemic Agents (8,10,14)**

| Medication            | Recommended Dosing With Impaired GFR (mL/min/1.73 m²) | Use in Dialysis          |
|-----------------------|-------------------------------------------------------|--------------------------|
| **Biguanides**        |                                                       |                          |
| Metformin             | • U.S. prescribing information states: “Do not use if serum creatinine ≥ 1.5 mg/dl in men, ≥ 1.4 mg/dl in women”  |
|                       | • British National Formulary and the Japanese Society of Nephrology recommend cessation if eGFR < 30 | Contraindicated           |
| **Second-generation sulfonylureas** |                                                       |                          |
| Glipizide             | • No dose adjustment required                        | No dose adjustment required |
| Glimepiride           | • Initiate conservatively at 1 mg daily              | Initiate conservatively at 1 mg daily |
| Glyburide             | • Avoid use                                          | Avoid use                 |
| **Meglitinides**      |                                                       |                          |
| Repaglinide           | • Initiate conservatively at 0.5 mg with meals if eGFR < 30 | No clear guidelines exist |
| Nateglinide           | • Initiate conservatively at 60 mg with meals if eGFR < 30 | No clear guidelines exist |
| **TZDs**              |                                                       |                          |
| Pioglitazone          | • No dose adjustment required                        | 15–30 mg daily has been used |
| **Alpha-glucosidase inhibitors** |                                                       |                          |
| Acarbose              | • Avoid if eGFR < 30                                  | Avoid use                 |
| Miglitol              | • Avoid if eGFR < 25                                  | Avoid use                 |
| **GLP-1 receptor agonists** |                                                       |                          |
| Exenatide             | • Not recommended with eGFR < 30                      | Avoid use                 |
| Liraglutide           | • No dose adjustment recommended by manufacturer    | Manufacturer recommends cautious use |

**TABLE CONTINUED ON P. 216**
### TABLE 1. Dosing Recommendations for Noninsulin Antihyperglycemic Agents (8,10,14), continued from p. 215

| Medication       | Recommended Dosing With Impaired GFR (mL/min/1.73 m²) | Use in Dialysis                                      |
|------------------|-------------------------------------------------------|-----------------------------------------------------|
| Albiglutide      | • No dose adjustment required for eGFR 15–89, per manufacturer | No specific dose adjustment recommended by manufacturer |
| Dulaglutide      | • No dose adjustment recommended by manufacturer      | No dose adjustment recommended by manufacturer       |
| **DPP-4 inhibitors** |                                                      |                                                     |
| Sitagliptin      | • 100 mg daily if eGFR >50                            | 25 mg daily                                         |
|                  | • 50 mg daily if eGFR 30–50                           |                                                     |
|                  | • 25 mg daily if eGFR <30                             |                                                     |
| Saxagliptin      | • 5 mg daily if eGFR >50                              | 2.5 mg daily                                        |
|                  | • 2.5 mg daily if eGFR ≤50                            |                                                     |
| Linagliptin      | • No dose adjustment required                         | No dose adjustment required                         |
| Alogliptin       | • 25 mg daily if eGFR >60                             | 6.25 mg daily                                       |
|                  | • 12.5 mg daily if eGFR 30–60                         |                                                     |
|                  | • 6.25 mg daily if eGFR <30                           |                                                     |
| Amylinomimetics  |                                                       |                                                     |
| Pramlintide      | • No dose adjustment required with eGFR >30           | Avoid use                                           |
|                  | • Not recommended with eGFR <30                       |                                                     |
| **SGLT2 inhibitors** |                                                   |                                                     |
| Canagliflozin    | • No dose adjustment required if eGFR ≥60             | Avoid use                                           |
|                  | • 100 mg daily if eGFR 45–59                          |                                                     |
|                  | • Avoid use and discontinue in patients with eGFR <45 |                                                     |
| Dapagliflozin    | • Avoid use if eGFR <60                               | Avoid use                                           |
| Empagliflozin    | • No dose adjustment required if eGFR ≥45             | Avoid use                                           |
|                  | • Avoid use and discontinue in patients with eGFR <45 |                                                     |
ported by published case reports (21), current evidence suggests that the overall risk of MALA is low (20,22). In fact, studies have shown that circulating lactate levels among metformin-treated individuals—even those with impaired kidney function—are typically in the normal range (20).

It has been suggested that eGFR may be a more appropriate measure to assess metformin use when considering that the SCr level can translate into varying eGFR levels depending on a patient’s race, age, and muscle mass (10). A recent review proposed that metformin use should be reevaluated at an eGFR <45 mL/min/1.73 m², with a reduction in maximum dose to 1,000 mg/day (20). The review further recommends metformin discontinuation when eGFR falls to <30 mL/min/1.73 m² (Table 2) (20).

**Sulfonylureas and Glinides**

Hypoglycemia is a primary treatment concern with insulin secretagogue use in general and is of particular importance in the context of DKD (8). Glyburide is extensively metabolized in the liver into several active metabolites that are excreted by the kidney and is not recommended for use in DKD (10,23). Glimepiride is associated with less hypoglycemia when compared to glyburide and should be initiated at a low dose and titrated conservatively, if used (24). Glipizide is metabolized by the liver into several inactive metabolites, and its clearance and elimination half-life are not affected by a reduction in eGFR; thus, specific dose adjustments in patients with DKD are not necessary, and glipizide is generally considered the sulfonylurea of choice in this population (25).

Similar to the sulfonylureas, the main concern with the use of glinides in the setting of DKD is an increased risk of hypoglycemia resulting from decreased renal clearance of the parent drugs and their metabolites (10,26,27). Lower doses of glinides are generally required in people with DKD; hence, these drugs should be started at conservative doses.

**Thiazolidinediones**

The thiazolidinediones (TZDs) are nearly completely metabolized by the liver (28–30). Despite the lack of a need for dosage adjustments in patients with DKD, TZD use is generally avoided in this population because of side effects such as refractory fluid retention and increased fracture risk (10,31). Of note for the DKD population, fluid retention secondary to TZD therapy can contribute to the development of heart failure.

**Glucagon-Like Peptide-1 Receptor Agonists**

Glucagon-like peptide-1 (GLP-1) receptor agonist use has been associated with post-marketing reports of decreased kidney function (32), yet such events have not been noted in clinical trials or population-based observational studies to date (33–35). The majority of case reports of altered kidney function with exenatide have involved at least one contributory factor such as congestive heart failure, pancreatitis, infection, or the use of concomitant medications such as diuretics, renin-angiotensin-aldosterone system inhibitors, and nonsteroidal anti-inflammatory drugs (32). Additionally, patients who experience gastrointestinal adverse events (i.e., nausea, vomiting, or diarrhea) associated with GLP-1 receptor agonist treatment appear to be at greatest risk because these symptoms contribute to a state of dehydration. Table 1 provides current renal dosing recommendations from the manufacturers of currently available GLP-1 receptor agonists.

**Dipeptidyl Peptidase-4 Inhibitors**

Potential advantages of dipeptidyl peptidase-4 (DPP-4) inhibitor use in DKD are their low risk of hypoglycemia and general weight neutrality (36,37). All of the currently available DPP-4 inhibitors are labeled for use in DKD, but sitagliptin, saxagliptin, and alogliptin require downward dose titration based on eGFR (Table 1) (38). Linagliptin, in contrast, does not require dose adjustment based on renal function (39).

Recent findings from a large cardiovascular outcomes study with saxagliptin indicated a higher risk of hospitalization for heart failure in patients receiving saxagliptin (40). In response to these findings, a meta-analysis of randomized clinical trials of DPP-4 inhibitors was conducted showing the overall risk of acute heart failure to be higher in patients treated with DPP-4 inhibitors than in those treated with placebo or an active comparator (41). Although these findings have raised questions about DPP-4 inhibitors and cardiovascular outcomes, ongoing

---

**TABLE 2. Proposed Considerations for Metformin Use in DKD (20)**

| eGFR (mL/min/1.73 m²) | Proposed Action |
|-----------------------|-----------------|
| ≥60                   | • No renal contraindication to metformin  
|                       | • Monitor renal function annually |
| <60 and ≥45           | • Continue use  
|                       | • Increase monitoring of renal function (every 3–6 months) |
| <45 and ≥30           | • Prescribe metformin with caution  
|                       | • Use lower dose (e.g., 50% or half-maximal dose)  
|                       | • Closely monitor renal function (every 3 months)  
| <30                   | • Do not start new patients on metformin  
|                       | • Stop metformin |

---

**Note:** The thiazolidinediones (TZDs) are nearly completely metabolized by the liver (28–30). Despite the lack of a need for dosage adjustments in patients with DKD, TZD use is generally avoided in this population because of side effects such as refractory fluid retention and increased fracture risk (10,31). Of note for the DKD population, fluid retention secondary to TZD therapy can contribute to the development of heart failure. **Glucagon-like peptide-1 (GLP-1) receptor agonist use has been associated with post-marketing reports of decreased kidney function (32), yet such events have not been noted in clinical trials or population-based observational studies to date (33–35). The majority of case reports of altered kidney function with exenatide have involved at least one contributory factor such as congestive heart failure, pancreatitis, infection, or the use of concomitant medications such as diuretics, renin-angiotensin-aldosterone system inhibitors, and nonsteroidal anti-inflammatory drugs (32). Additionally, patients who experience gastrointestinal adverse events (i.e., nausea, vomiting, or diarrhea) associated with GLP-1 receptor agonist treatment appear to be at greatest risk because these symptoms contribute to a state of dehydration. Table 1 provides current renal dosing recommendations from the manufacturers of currently available GLP-1 receptor agonists.**

**Dipeptidyl Peptidase-4 (DPP-4) inhibitors** Potential advantages of dipeptidyl peptidase-4 (DPP-4) inhibitor use in DKD are their low risk of hypoglycemia and general weight neutrality (36,37). All of the currently available DPP-4 inhibitors are labeled for use in DKD, but sitagliptin, saxagliptin, and alogliptin require downward dose titration based on eGFR (Table 1) (38). Linagliptin, in contrast, does not require dose adjustment based on renal function (39).

Recent findings from a large cardiovascular outcomes study with saxagliptin indicated a higher risk of hospitalization for heart failure in patients receiving saxagliptin (40). In response to these findings, a meta-analysis of randomized clinical trials of DPP-4 inhibitors was conducted showing the overall risk of acute heart failure to be higher in patients treated with DPP-4 inhibitors than in those treated with placebo or an active comparator (41). Although these findings have raised questions about DPP-4 inhibitors and cardiovascular outcomes, ongoing
Sodium–Glucose Cotransporter 2 Inhibitors

Three sodium–glucose cotransporter 2 (SGLT2) inhibitors are currently available in the U.S. (Table 1). SGLT2 inhibitors improve glycemia by increasing disposal of glucose via the urine (42). Because of diminished efficacy as kidney function falls, canagliflozin and empagliflozin are not recommended for use when eGFR is <45 mL/min/1.73 m², and dapagliflozin is not recommended when eGFR is <60 mL/min/1.73 m². SGLT2 inhibitors have been associated with an initial slight decrease in eGFR in clinical trials. This decrease in eGFR may be a hemodynamic effect to decrease glomerular hyperfiltration, with eGFR trending back toward baseline with continued treatment (43).

Recent case reports of euglycemic diabetic ketoacidosis (eDKA) have been reported in patients receiving treatment with SGLT2 inhibitors. It is currently not known whether DKD alters the risk of eDKA in those receiving SGLT2 inhibitor therapy. In a recent U.S. Food and Drug Administration drug safety communication on SGLT2 inhibitor–associated DKA, however, hypovolemia and acute renal impairment were listed as potential factors that may contribute to the development of high anion gap metabolic acidosis (44). Additionally, SGLT2 inhibitors appear to place patients with renal impairment at increased risk of hyperkalemia, particularly when used in combination with potassium-sparing diuretics, ACE inhibitors, and angiotensin II receptor blockers. Health care providers should be cognizant of these potential risks and monitor appropriately.

Longer-term follow-up in large groups of patients with DKD is needed to confirm the safety of SGLT2 therapy in patients with kidney disease (8).

Conclusion

Glycemic management in patients with DKD is complicated by a variety of factors, including, but not limited to, imprecision of A1C measurement and altered pharmacokinetics of antidiabetic agents. Appropriate glycemic goal-setting and use of SMBG are crucial to avoiding hyperglycemia in this population.

Duality of Interest

Dr. Neumiller has received research grant support from AstraZeneca, Janssen, Merck, and Novo Nordisk; has been a consultant to Janssen and Sanofi; and has been a speakers’ bureau member for Janssen and Novo Nordisk. Dr. Hirsch has received grant support from Novo Nordisk and Sanofi and has been a consultant to Abbott, Roche, and Valeritas. No other potential conflicts of interest relevant to this article were reported.

References

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–2539
2. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, Md., National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013, sections 1.7.2 and 1.8.2
3. American Diabetes Association. Microvascular complications and foot care. Sec. 9 in Standards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S58–S66
4. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473–1478
5. Yos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 2011;58:591–598
6. Nakao T, Matsumoto H, Okada T, et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826–830
7. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011;171:1920–1927
8. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 2014;37:2864–2883
9. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal glucose homeostasis: its importance in human glucose homeostasis. Diabetes Care 2001;24:382–391
10. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850–886
11. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycemia treatment approach, and glycated hemoglobin concentration on the risk of severe hyperglycemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
12. Kalantar-Zadeh K. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint. Diabetes Care 2012;35:1625–1628
13. Ramirez SP, McCullough KP, Thumma JR, et al. Hemoglobin A1c levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care 2012;35:2527–2532
14. Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:1611–1620
15. Mühlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 1991;14:344–346
16. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529–550
17. Charpentier G, Riveline JP, Varraud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl. 4):73–85
18. Glucophage (metformin hydrochloride) [final printed labeling]. US Food and Drug Administration. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/200020357809_Diabetes.pdf. Accessed 8 May 2015
19. Roberts F, Ryan GJ. The safety of metformin in type I diabetic patients with impaired kidney function. Diabetes Care 2001;24:382–391
20. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in heart failure. Ann Pharmacother 2012;46:320–332
21. Kalantar-Zadeh K, Uppot RN, Lewandowski KB. Case records of the Massachusetts General Hospital, Case
n e u m i l l e r a n d h i r s c h

23-2013: a 54-year-old woman with abdominal pain, vomiting, and confusion. N Engl J Med 2013;369:374–382

22. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;CD002967

23. Rydberg T, Jönsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026–1030

24. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467–473

25. Harrower AD. Pharmacokinetics of oral antihyperglycemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111–119

26. Nagai T, Imamura M, Lizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003;59:191–194

27. Hasslacher C, for the Multinational Regaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886–891

28. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompör T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368–374

29. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003;43:252–259

30. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002;30:391–399

31. Grey AB. Skeletal toxicity of thiazolidinediones. Ann Intern Med 2008;148:563

32. U.S. Food and Drug Administration. Byetta (exenatide)—renal failure. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm. Accessed 7 May 2015

33. Tuttle KR, Heilmann C, Hoogwerf BJ, Brown C, Anderson PW. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis 2013;62:396–398

34. Pawaskar M, Tuttle KR, Li Q, Best JJ, Anderson PW. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann Pharmacother 2014;48:571–576

35. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345–355

36. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes: a review and meta-analysis. Diabetes Obes Metab 2012;14:762–767

37. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247–1258

38. Giorda CB, Nada E, Taraglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment: a systematic review of the literature. Endocrine 2014;46:406–419

39. Friedrich C, Emser A, Woerle HJ, Graef-Mody U. Renal impairment has no clinically relevant effect on the long-term exposure of lixinaglutin in patients with type 2 diabetes. Am J Ther 2013;20:618–621

40. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–1326

41. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689–697

42. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transporter 2 inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377–385

43. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. Circulation 2014;129:587–597

44. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed 2 June 2015